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Abbreviations used
CVID: Common variable immunodeficiency
ESID: European Society for Immunodeficiencies
GC: Germinal center
HD: Healthy donor
IgAdef: Selective IgA deficiency
IgG/Adef: IgG subclass deficiency with IgA deficiency
IgH: Immunoglobulin heavy chain
IUIS: International Union of Immunological Societies
LLN: Lower limit of normal
MBC: Memory B cell
NPV: Negative predictive value
PAD: Predominantly antibody deficiency
PC: Plasma cell
PPV: Positive predictive value
sm: Surface membrane
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810 BLANCO ET ALBackground: Predominantly antibody deficiencies (PADs) are
the most prevalent primary immunodeficiencies, but their B-cell
defects and underlying genetic alterations remain largely
unknown.
Objective: We investigated patients with PADs for the
distribution of 41 blood B-cell and plasma cell (PC) subsets,
including subsets defined by expression of distinct
immunoglobulin heavy chain subclasses.
Methods: Blood samples from 139 patients with PADs, 61
patients with common variable immunodeficiency (CVID), 68
patients with selective IgA deficiency (IgAdef), 10 patients with
IgG subclass deficiency with IgA deficiency, and 223 age-
matched control subjects were studied by using flow cytometry
with EuroFlow immunoglobulin isotype staining. Patients were
classified according to their B-cell and PC immune profile, and
the obtained patient clusters were correlated with clinical
manifestations of PADs.
Results: Decreased counts of blood PCs, memory B cells
(MBCs), or both expressing distinct IgA and IgG subclasses
were identified in all patients with PADs. In patients with
IgAdef, B-cell defects were mainly restricted to surface
membrane (sm)IgA1 PCs and MBCs, with 2 clear subgroups
showing strongly decreased numbers of smIgA1 PCs with
mild versus severe smIgA1 MBC defects and higher
frequencies of nonrespiratory tract infections, autoimmunity,
and affected family members. Patients with IgG subclass
deficiency with IgA deficiency and those with CVID showed
defects in both smIgA1 and smIgG1 MBCs and PCs.
Reduced numbers of switched PCs were systematically found
in patients with CVID (absent in 98%), with 6 different
defective MBC (and clinical) profiles: (1) profound decrease
in MBC numbers; (2) defective CD271 MBCs with almost
normal IgG3
1 MBCs; (3) absence of switched MBCs; and (4)
presence of both unswitched and switched MBCs without
and; (5) with IgG2
1 MBCs; and (6) with IgA1
1 MBCs.
Conclusion: Distinct PAD defective B-cell patterns were
identified that are associated with unique clinical profiles. (J
Allergy Clin Immunol 2019;144:809-24.)
Key words: Immunodeficiency, primary antibody deficiency, selec-
tive IgA deficiency, common variable immunodeficiency, immuno-
phenotyping, immunoglobulins, immunoglobulin subclasses,
memory B cells, plasma cells, flow cytometry, diagnosis,
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responsible for PADs are detected in less than 10% of cases.1,2,11
In such settings altered distributions of distinct blood B- and T-
cell subpopulations determined by using flow cytometry might
provide key (complementary) diagnostic information, particu-
larly for patients with low serum antibody isotype levels and
nonspecific clinical features.5,12,13 Thus controversial results
have been reported in patients with CVID concerning the poten-
tial association between specific B-cell alterations, such as
decreased (relative) numbers of CD271 (antigen-experienced)
switched B cells in blood and relevant clinical manifestations
(eg, splenomegaly, granulomatous disease, and autoimmu-
nity),14-18 whereas preservation of CD271 class-switched mem-
ory B cells (MBCs) has been considered a surrogate marker for
the ability to respond to vaccination.5 Similarly, decreased
CD271 (antigen-experienced) switched B-cell counts in blood
have been associated with a worse clinical outcomes in patients
with IgAdef,19 whereas decreased percentages of CD211 B cells
and increased proportions of immature/transitional B-cells have
both been correlated to distinct CVID clinical profiles.15,18,20
Despite all the above associations, the actual clinical relevance
of these B-cell defects in patients with PADs still remains elusive.
In addition, a significant clinical and functional B-cell heteroge-
neity is still observed among patients who present with similar
patterns of alteration of B cells by using flow cytometry (eg,
reduced numbers of switchedMBCs).18,21 This is probably due to
the limited number of B-cell populations investigated, the lack of
appropriate age-matched reference ranges, or both in most
studies. For example, in many studies focused on antigen-
experienced B cells, no distinction is made between (relative
long-living) MBCs and (newly generated) circulating plasma
cells (PCs),14,15,19 and very few reports have investigated the pre-
cise relationship between defects in specific immunoglobulin iso-
types and the number of blood B cells and PCs that express
them.22,23 Moreover, thus far, no study has investigated the
IgG1 to IgG4 and IgA1 and IgA2 subclass distribution within the
PC and MBC compartments of patients with PADs. Finally,
despite the fact that PADs can present at any age1,7,9,13 and major
age-related differences exist in the distribution of blood B-cell
subsets throughout life,24 most reports on B-cell compartments
in patients with PADs do not consider (normal) age-associated
variations, and only a few studies subdivided healthy donors
(HDs) and patients with PADs into a few (n 5 3-4) age
groups.17,20,23 Altogether, this reflects the potential relevance of
a more in-depth evaluation of the B-cell compartment and its al-
terations in patients with PADs versus age-matched control sub-
jects for improved diagnosis and classification of PADs.
Here, for the first time, we investigated the distribution of 41
distinct blood B-cell and PC subsets in 139 patients with PADs
versus 223 age-matched control subjects. Based on the B-cell and
PC defects encountered, distinct defective immune profiles were
identified that are associated with both the diagnostic subtype and
clinical manifestations of PADs.METHODS
Patients and control subjects
Overall, 139 patients with PADs4 (mean age, 32 6 19 years; range, 4-
87 years) and 223 HDs (mean age, 39 6 28 years; range, 4-99 years) were
studied. Patients with PADs were subclassified by the International Union
of Immunological Societies (IUIS)4 and European Society forImmunodeficiencies (ESID)5 criteria into 68 and 42 patients with IgAdef
(mean age, 24 6 17 years), respectively; 10 patients with IgG/Adef (mean
age, 24 6 14 years); and 61 patients with CVID (mean age, 41 6 17 years).
Twenty-six asymptomatic patients with IgAdef (mean age, 24 6 15 years)
with serum IgA levels of less than 7 mg/dL did not fulfill the ESID criteria5
for IgAdef and are referred to hereafter as ESID2 versus ESID1 IgAdef cases.
EDTA-anticoagulated blood samples were collected at 8 different sites and
centrally processed in 2 of them after informed consent was provided by
each subject, their legal representatives, or both. The study was approved by
local ethics committees.Flow cytometric identification of blood B cells and
their subsets
Total B-cell counts and distribution of 41 distinct B-cell subsets were
analyzed by using flow cytometry after staining 107 nucleated cells with the
EuroFlow 12-color immunoglobulin isotype B-cell tube (see Table E1 in
this article’s Online Repository at www.jacionline.org) and bulk-lyse standard
operating procedure (www.EuroFlow.org), as described elsewhere.25,26 Per
sample, 5 3 106 or more leukocytes were measured in LSRFortessa X-20
flow cytometers (Becton Dickinson Biosciences, San Jose, Calif). Instrument
set-up and calibration were performed according to EuroFlow standard oper-
ating procedures (www.EuroFlow.org).27 For data analysis, Infinicyt software
(Cytognos S.L., Salamanca, Spain) was used.
CD191 B-cells and PCs were both identified by using low-to-intermediate
forward light scatter and sideward light scatter and subsequently subclassified
into 41 different subpopulations based on their maturation stage and expres-
sion of distinct immunoglobulin isotypes and immunoglobulin subclasses,
as previously described,24 by using the gating strategy detailed in the
Methods section and Fig E1 in this article’s Online Repository at www.
jacionline.org. Briefly, the following B-cell subpopulations were defined
based on their staining profile for CD19, CD38, CD24, CD21, CD27, CD5,
surface membrane (sm)IgM, and smIgD: (1) CD272CD38hi
CD24hiCD51smIgM11IgD1 immature/transitional B-cells, (2) CD272
CD38loCD24hetCD5hetsmIgM1IgD11 naive B lymphocytes; (3) CD271
CD38loCD52CD24hetsmIgM11IgD1 unswitched MBCs; (4) CD271/
2CD38loCD52CD24hetsmIgM2IgD2 switched MBCs; and (5) CD2711
CD38hiCD52CD212CD242 PCs. MBCs and PCs were further subclassified
according to their immunoglobulin isotypes and immunoglobulin subclasses
into (1) smIgM11IgD1, smIgD1-only, smIgA1
1, smIgA2
1, smIgG1
1,
smIgG2
1, smIgG3
1, and smIgG4
1 MBCs and (2) smIgM1-only, smIgD1-
only, smIgA1
1, smIgA2
1, smIgG1
1, smIgG2
1, smIgG3
1, and smIgG4
1
PCs, respectively. Finally, the above subpopulations of naive B lymphocytes
and MBCs were placed in further subsets based on CD21 (CD211 vs
CD212 naive and MBC subsets) and CD27 expression (CD271 and CD272
MBCs, see Fig E1). Absolute counts were calculated by using total B-cell
counts based in a double-platform assay28 and used throughout the study. In-
tralaboratory and interlaboratory variability was assessed at the participating
centers based on replicate measurements of the same samples to ensure com-
parable results at distinct sites (see Fig E2 in this article’s Online Repository at
www.jacionline.org).Statistical analyses
Statistical analyses were performed with either the R (version 3.2.3; https://
www.r-project.org/)29 or SPSS (version 23.0; IBM, Armonk, NY) software
packages. Kruskal-Wallis andMann-WhitneyU tests (for continuous variables)
and x2 and Fisher exact tests (for categorical variable) were used, respectively,
to investigate the statistical significance (set at P <_ .05) of differences observed
between groups in B-cell subset counts and clinical features. Unsupervised
clustering analysis of patient data based on the K-means learning algorithm30
and Euclidean distances was performed by using blood B-cell subset absolute
counts normalized by age group (see Table E2 in this article’s Online Reposi-
tory at www.jacionline.org) based on (previously reported) reference values of
140 age-matched subjects24 and extended here to 223 individual2log10 values
(patient value/minimum normal value)2. Age-normalized B-cell/PC subset
values per patient were represented in heat maps by using gplots (R package),31
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group defined by aminimumof 20 subjects (see Table E3 in this article’s Online
Repository at www.jacionline.org). Those B-cell and PC subsets with absolute
counts that were less than the method’s limit of detection (undetectable;
<0.01 cells/mL) in at least 1 subject for more than 1 reference (HD) age group
were excluded from the analysis (ie, IgD-only and IgG4
1 PCs and MBCs and
IgG1
1, IgG2
1, and IgG3
1 PCs).RESULTS
Blood B-cell and PC subset defects in patients with
IgAdef
Once compared with age-matched HDs, most patients with
IgAdef displayed normal total B-cell counts (93%), including
normal immature/transitional (90%), naive (94%), and MBC
(87%) counts (see Table E4 in this article’s Online Repository at
www.jacionline.org). In contrast, numbers of (total) PCs,
although being detected in every case (>_0.07 PCs/mL), were
decreased in 49% of patients (Fig 1 and see Table E4). When
MBCs and PCs were dissected according to their pattern of
expression of immunoglobulin subclasses, a greater frequency
of altered cases was observed. Thus smIgA1
1 and/or smIgA2
1
PC counts were found to be reduced in blood in 97% of cases,
with still detectable residual smIgA1 PCs in 38% of the patients
(PCs expressing both IgA subclasses were found in 26%,
smIgA11-only subclasses were found in 9%, and smIgA2
1-
only subclasses were found in 3% of all patients with IgAdef).
In line with these findings, reduced smIgA1
1 and/or smIgA2
1
MBC counts were also observed in virtually all patients with IgA-
def (99%), although still present in half (50%) of them (both
smIgA1
1 and smIgA2
1 MBCs were detected in 40% and
smIgA11-only MBCs were detected in 10% of all patients with
IgAdef; Fig 2 and see Table E4). Thus decreased smIgA1
1 or
smIgA2
1MBC counts showed a sensitivity of 99% with a nega-
tive predictive value (NPV) of 100% (see Table E5 in this article’s
Online Repository at www.jacionline.org), although when com-
bined with decreased smIgA1
1 or smIgA2
1 PC counts, reached
a 100% sensitivity and NPV (see Table E6 in this article’s Online
Repository at www.jacionline.org). In turn, absence of the above
MBC or PC subpopulations showed a specificity of 100% and
positive predictive value (PPV) of 98% for identification of pa-
tients with IgAdef (see Table E6). In contrast, smIgG1 PCs
were present in virtually every patient with IgAdef (91%), with
normal smIgG1 PC counts in 71% of them. Similarly, smIgG1
to smIgG3
1MBCcounts were only decreased in 13%or fewer pa-
tients (Fig 1 and see Fig E3 and Table E4).Blood B-cell and PC subset defects in patients with
IgG/Adef
Similarly to patients with IgAdef, total peripheral blood B-cell
counts, including immature/transitional, naive and MBC counts,
were within the normal range in most patients with IgG/Adef
(90%, Fig 2 and see Table E4); in contrast, decreased PC counts
were observed in 90% of patients with IgG/Adef, mostly because
of a significant decrease in both smIgA1 and smIgG1 PC counts
(100% and 90%, respectively), which were undetectable in 90%
and 50% of cases, respectively. Although total bloodMBC counts
were within the normal range in 70% of patients with IgG/Adef
showed decreased smIgA1
1 MBC and/or smIgA2
1MBC counts
in association with decreased smIgG2
1MBC counts; meanwhile,smIgG1
1 and smIgG3
1 MBC counts were normal in 80% and
90% of patients with IgG/Adef, respectively (Fig 1 and see Fig
E3 and Table E4).
Based on these results, the observation of undetectable PCs
combined with decreased smIgG2
1 MBC counts also showed a
high sensitivity (90%), specificity (96%), and NPV (100%) for
IgG/Adef in addition to those MBC and PC populations that iden-
tified IgAdef. In contrast, the PPV was only 50% because of the
low number of patients with IgG/Adef analyzed (Fig 1 and see
Tables E6 and E7 in this article’s Online Repository at www.
jacionline.org).Blood B-cell and PC subset defects in patients with
CVID
In contrast to patients with IgAdef, total B-cell and PC counts
were decreased in around half (51%) and the majority (98%) of
patients with CVID, respectively (P <.001 vs patients with IgA-
def). In addition, immature/transitional and naive B lympho-
cytes were decreased in 42% and 43% of patients with CVID,
mostly at the expense of CD211 B cells (Fig 2 and see the
Results section, Fig E4, and Table E4 in this article’s Online Re-
pository at www.jacionline.org), with only 10% and 3% of pa-
tients with CVID showing undetectable immature/transitional
and naive B cells, respectively (Fig 2 and see Table E4). Reduced
smIgA1
1 and/or smIgA2
1 PC counts were found in all patients
with CVID, being undetectable in virtually every (98%) case.
In line with these findings, only 2% of patients with CVID
showed circulating smIgG1 PCs (Fig 1 and see Fig E3 and
Table E4). Thus the absence of switched PCs was highly accu-
rate (100% specificity, 100% PPV, and 100% NPV, with a sensi-
tivity of 98%) for identification of CVID (see Table E8 in this
article’s Online Repository at www.jacionline.org). Of note,
no other parameter or combination of parameters showed an
improved sensitivity, specificity, PPV, and NPV for identifica-
tion of CVID than the absence of switched PCs or the lack of
smIgA2
1 PCs (see Table E6). However, the lack of switched
PCs was not specific enough for an accurate differential diag-
nosis among distinct PAD subgroups because 9% of patients
with IgAdef and 50% of patients with IgG/Adef also had unde-
tectable switched PCs. Because of this, for a clear-cut discrimi-
nation among distinct PAD diagnostic categories, the lack of
switched PCs needs to be combined with the absence or decrease
in other B-cell subsets in patients with CVID that are typically
normal among patients with IgAdef and those with IgG/Adef
(eg, smIgG1
1 or smIgG2
1 MBCs, or total PCs; Fig 1 and see
Table E4). Interestingly, the (small) subgroup of patients with
IgAdef who had undetectable switched PCs also had lower
serum IgG levels at diagnosis (data not shown).
Finally, despite abnormally low total MBC counts being
observed in most patients with CVID (70%) and being undetect-
able (<0.01 MBCs/mL) in only 13% of cases, the degree of
involvement of MBCs expressing different immunoglobulin
isotypes and immunoglobulin subclasses varied significantly.
Thus reduced smIgA1
1 and/or smIgA2
1 MBC counts were
observed in virtually all patients with CVID (98%), being absent
in most of them (80%). Regarding MBC subsets expressing
distinct IgG subclasses, patients with CVID more frequently
showed decreased or absent smIgG2
1 (95% and 67% of patients,
respectively) than smIgG1
1MBC counts (90% and 33% [P > .05
AB
Criteria for diﬀerenal diagnosis HD
(n=223)
IgAdef
(n=68)
IgG/Adef
(n=10)
CVID
(n=61)
HD vs. PAD
Strongly ↓ smIgA1+/smIgA2+ PCs or MBCs NO(0/223)
YES
(68/68)
YES
(10/10)
YES
(61/61)
TOTAL 0/223 68/68 10/10 61/61
IgAdef vs. CVID
Undetectable smIgG2+ MBCs
or
Undetectable total PCs (<0.01 cells/μL)
NO
(0/68)
NO
(0/68)
NO
(3/10)
YES
(5/10)
YES
(41/61)
YES
(55/61)
TOTAL 0/68 6/10 59/61
IgAdef vs. IgG/Adef
↓ smIgG2+ MBCs
or
Undetectable total PCs (<0.01 cells/μL)
NO
(8/68)
NO
(0/68)
YES
(8/10)
YES
(5/10)
YES
(58/61)
YES
(55/61)
TOTAL 8/68 9/10 61/61
CVID vs. IgG/Adef
Undetectable switched PCs (<0.01 cells/μL)
and
↓ smIgG1+ MBCs
NO
(6/68)
NO
(9/68)
YES
(5/10)
NO
(2/10)
YES
(60/61)
YES
(55/61)
TOTAL 0/68 1/10 54/61
Reduced smIgA1+/
smIgA2+
PCs or MBCs
Reduced
smIgG2+
MBCs
No switched
PCs
(<0.01 
cells/μl)
No PCs
(<0.01 
cells/μl)
Reduced
smIgG1+
MBCs
IgAdef
n=68 
CVID
n=61 
8 7
11
60 54
8
IgG/Adef
n=10 
Healthy donors (n=223)
Normal smIgA1+/smIgA2+ PCs or MBCs
(Strongly) reduced smIgA1+/smIgA2+ PCs or MBCs (n=139)
Predominantly anbody deﬁciency (PAD) paents
compared to
FIG 1. Alterations in blood B-cell and PC subset counts useful for the diagnosis of PADs and for the
differential diagnosis of IgAdef versus IgG/Adef versus CVID. A, Scheme illustrating the most useful periph-
eral blood B-cell subset alterations for the diagnosis of PADs (vs HDs; strongly reduced: absolute numbers
lower than the minimum value in HDs) and the differential diagnosis of patients with IgAdef versus patients
with IgG/Adef versus patients with CVID are shown. As displayed, these criteria showed a 100% and approx-
imately 98% accuracy in the diagnosis of PADs and the discrimination between IgAdef and CVID, respec-
tively, whereas approximately 10% of cases within both diagnostic subgroups overlapped with 10% and
10% of patients with IgG/Adef, respectively. B, Most useful peripheral blood B-cell subset criteria for the
diagnosis of PAD versus HDs and the distinction between patients with IgAdef versus patients with CVID,
patients with IgAdef versus patients with IgG/Adef, and patients with CVID versus patients with IgG/Adef
are shown, together with the number of cases within the different diagnostic categories that fulfilled these
criteria.
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FIG 2. Absolute counts of distinct maturation-associated subpopulations of blood B cells and PCs (A) and
total switched, total IgA, and IgA subclass subsets of MBCs (B) and PCs (C) in patients with IgAdef (n 5 68),
patients with IgG/Adef (n 5 10), and patients with CVID (n 5 61) versus HDs (n 5 223) grouped by age. In-
dividual cases are represented as green dots (IgAdef), yellow dots (IgG/IgAdef), red dots (CVID), and gray
dots (HDs). Dotted gray lines represent age-associated reference 5th and 95th values. Percentages of pa-
tients with reduced numbers compared with reference values per age group are depicted above each
plot by using the same color code.
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2019
814 BLANCO ET AL
J ALLERGY CLIN IMMUNOL
VOLUME 144, NUMBER 3
BLANCO ET AL 815and P < .001], respectively) and smIgG3
1MBC counts (61% and
23%, respectively; P < .001; Fig 1 and see Fig E3 and Table E4).Classification of patients with PADs based on blood
B-cell and PC subset immune profiles
Unsupervised clustering analysis identified 5 major immune
profiles of altered blood B-cell and PC subset counts in patients
with PADs (classification criteria are provided in Table I), which
were closely related to the IUIS diagnostic categories of PADs
and are termed hereafter PAD-1 to PAD-5 (Fig 3, A).4 Thus pa-
tients with IgAdef were split between the PAD-1 and PAD-2 clus-
ters (with 1 outlier in PAD-3), and patients with IgG/Adef were
split between the PAD-1, PAD-2, and PAD-3 groups, whereas
most (54/61) patients with CVID fell into the PAD-3, PAD-4,
and PAD-5 clusters, with 7 of 61 outliers falling into the PAD-1
and PAD-2 groups (Fig 3, A).
In detail, PAD-1 included 40 patients with reduced but detect-
able numbers of smIgA1 PCs and/or smIgA1 MBCs (smIgA1
MBCs and smIgA1 PCs ranging from <12-fold below the lower
limit of normal [LLN] and undetectable to virtually normal
counts, respectively). Thirty-two (80%) of 40 PAD-1 cases had
been given a previous diagnosis of IgAdef and 2 (5%) of IgG/
Adef, and 6 (15%) were patients with CVID with decreased but
detectable numbers of IgA1
1 or IgA2
1MBCs with limited effect
on the overall number of smIgA1 MBCs (never decreased >12
times the LLN) and virtually normal IgG1
1 to IgG3
1 MBC
counts.
PAD-2 was characterized by severely decreased numbers of
smIgA1MBCs (>40 times below the LLN; absent in 37 of 39 pa-
tients) and absence of smIgA1 PCs but (similarly to PAD-1) virtu-
ally normal smIgG1
1 to smIgG3
1 MBC counts. This PAD-2
cluster included 35 (90%) patients with IgAdef, 3 (7.5%) patients
with IgG/Adef, and 1 (2.5%) patient with CVID who lacked PCs
and smIgA1 MBCs but had normal smIgG1 MBC numbers.
PAD-3 cases consisted of patients with severely decreased
switched smIgG1 and smIgA1 PC counts (absent in 34/35 cases)
and smIgA1
1/smIgA2
1 MBC counts (absent in 30/36 cases) but
presenting with a heterogeneous defect on IgG1MBCs, consist-
ing of severely reduced smIgG2
1MBC counts (absent in 19/36),
with a milder decrease in smIgG1
1 (86% of cases) and particu-
larly smIgG3
1 (39% of cases) MBC counts. This subgroup
included 30 patients with CVID (83%), 5 patients with IgG/
Adef (14%), and 1 patient with IgAdef (3%).
Finally, all PAD-4 and PAD-5 cases had undetectable smIgG2
1
MBCs (14/14 cases) with severely reduced smIgG1
1MBC counts
(14/14; absent in 9/14 cases; PAD-4) or no MBCs at all (PAD-5),
except for 2 PAD-5 cases who showed detectable IgG3
1MBCs at
levels of greater than 15-fold below the LLN; all PAD-4 and PAD-
5 cases corresponded to CVID.Blood B-cell and PC immune profiles in patients
with IgAdef
Patients with IgAdef were split into 2 subgroups termed
hereafter IgAdef-1 and IgAdef-2 (classification criteria are pro-
vided in Table I) with different patterns of alteration of smIgA1
MBCs (Fig 3, B): smIgA1
1 and/or smIgA2
1MBCs were present
in the IgAdef-1 group, whereas they were virtually absent in
IgAdef-2 cases (Fig 4, B, and Figs E5, A, and E6 in this article’s
Online Repository at www.jacionline.org). Interestingly, these 2subgroups did not show a strong association with the ESID diag-
nostic criteria5 for clinical IgAdef, which were met in 53% of
IgAdef-1 cases versus 69% of IgAdef-2 cases (P > .05; see
Table E9, A, in this article’s Online Repository at www.
jacionline.org). Of note, IgAdef-1 cases were older than
IgAdef-2 cases both at the time of analysis (31 6 19 years vs
17 6 13 years, respectively; P 5 .001) and at diagnosis
(28 6 19 years vs 14 6 13 years, respectively; P 5 .006), with
a similar male/female distribution. Despite no differences being
observed in IgM serum levels at diagnosis, serum IgG levels
were slightly lower in IgAdef-1 versus IgAdef-2 cases
(1305 6 290 vs 1467 6 232 mg/dL, P 5 .03). In turn, although
around one third of both IgAdef-1 and IgAdef-2 cases had a
past history of recurrent respiratory tract infections at presenta-
tion, IgAdef-2 cases showed a greater frequency of other (recur-
rent) infections (17% vs 0%, respectively; P 5 .02), tissue-
specific autoimmunity (31% vs 6%, respectively; P 5 .01), and
other family members affected (22% vs 3%, respectively;
P 5 .03; Fig 5, A, and see Table E10 in this article’s Online Re-
pository at www.jacionline.org).Blood B-cell and PC immune profiles in patients
with CVID
Overall, 6 subgroups of CVID (designated hereafter as CVID-1
to CVID-6) with different patterns of altered B-cell subsets and
complete absence of switched PCs in 98% of cases (classification
criteria are provided in Table I) were identified (Figs 3, C, and 4,
C, and see Figs E5, B, and E6).
The CVID-1 and CVID-2 groups included patients with both
detectable smIgMD1MBCs and switchedMBCs of all smIgG1 to
smIgG3 subclasses, with CVID-1 (but not CVID-2) cases also
presenting normal or slightly reduced IgA1
1 MBC counts. In
contrast, CVID-3 cases showed a more severe smIgG2
1 MBC
defect (>4-fold below the LLN), frequently with undetectable
(<0.01 cells/mL) smIgG2
1 MBCs (17/22 cases). CVID-4 cases
had no switched MBCs, whereas CVID-5 cases showed more se-
vere defects involving all CD271 MBC subsets (>_6-fold below
the LLN) but almost normal CD272 smIgG3
1 MBC counts.
Finally, CVID-6 cases had severely decreased switched and un-
switched MBC counts, including 0.06 or fewer IgG3
1 MBCs/
mL (>15-fold below the LLN; Figs 3, C, and 4, C).
Overall, a close association between the CVID-1 and CVID-6
clusters and the EUROclass classification (see Table E11 in this
article’s Online Repository at www.jacionline.org)18 of CVID
was observed. Thus EUROclass smB1 patients were subclassified
here into the CVID-1 (58%), CVID-2 (17%), and CVID-3 (25%)
clusters, depending on their normal versus low smIgA1 and
smIgG2
1 MBC counts. EUROclass B2 patients were included
in our CVID-6 cluster, except for 2 cases with less than 1% pe-
ripheral blood B cells but preserved MBC counts, who were
thereby classified as CVID-4 and CVID-5, respectively. In fact,
in 8 of 9 patients classified as B2, we could identify naive B cells,
and in 4 of 9 cases we could also identify MBCs, despite these
cells being severely decreased in 2 of them. In contrast, EURO-
class smB2 patients split across the different CVID-1 to CVID-
6 clusters: CVID-1, 2.5%; CVID-2, 10%; CVID-3, 47.5%;
CVID-4, 12.5%; CVID-5, 20%; and CVID-6, 7.5% of smB2
cases (Fig 3, C, and see Table E9, B). Inclusion of other EURO-
class parameters, such as CD21 expression (see Table E9, B) or
immature/transitional B-cell counts did not result in significantly
TABLE I. Criteria used for subclassification of patients with PAD, patients with IgAdef, and patients with CVID into the PAD-1 to
PAD-5, IgAdef-1 to IgAdef-2, and CVID-1 to CVID-6 clusters, respectively
Clusters
MBCs
Total MBCs CD271 MBCs CD211 MBCs smIgM11IgD1 MBCs Switched MBCs smIgA1 MBCs
PAD-1 Normal or Y<2-fold Normal or Y<1.4-fold Normal or Y<3-fold Normal or
Y<12-fold
PAD-2 Normal or Y<1.4-fold Normal or Y<1.1-fold Normal or Y<2-fold Y>40-fold or
undetectable
PAD-3 Normal or Y<10-fold Normal or Y<2-fold Normal or
Y<100-fold
Y>2-fold or
undetectable
PAD-4 Y1.4-46 fold Y>_2-fold or
undetectable§
Y>12-fold or
undetectable
Undetectable
PAD-5 Y>500-fold or
undetectable
Undetectable Y>190-fold or
undetectable
Undetectable
IgAdef-1 Normal or
Y<12-fold
IgAdef-2 Y >40-fold or
undetectable
CVID-1 Normal Normal or Y<1.4-fold Normal or
Y<1.8-fold
Normal or Y<1.4-fold Normal or Y<3-fold
CVID-2 Normal Normal Normal Normal Normal or Y<5-fold
CVID-3 Normal or Y<5-fold# Normal or Y<6-fold# Normal or
Y<8-fold#
Normal or Y<3-fold Y>3-100 fold
CVID-4 Y1.4-30 fold Y1.3-30 fold Y1.5-35 fold Normal or Y<14-fold Undetectable
CVID-5 Y5-45 fold Y>_6-fold or
undetectable
Y8-1000-fold Y>_3-fold or
undetectable
Y>2-80 fold
CVID-6 Y>500-fold or
undetectable
Undetectable Y>780-fold to
undetectable
Undetectable Y>185-fold or
undetectable
B-cell subpopulations that were not required for patient subclassification are plotted as empty cells. Undetectable is defined as less than 0.01 cells/mL. The most relevant subsets for
discrimination between 2 or more subgroups are highlighted in boldface.
*Less than 15% of cases showed reduced smIgG2
1 MBC counts systematically associated with the presence of switched PCs or normal to less than 2-fold reduced smIgA1 MBC
counts.
Those cases with smIgMD1 MBC counts reduced more than 2-fold systematically had normal smIgG3
1 MBC or detectable smIgG2
1 MBC counts.
One case had detectable switched PCs (55-fold below the LLN) associated with decreased smIgG1
1 (>1.5-fold) and smIgG2
1 MBC counts and undetectable smIgA1 MBCs.
§One case had normal values associated with undetectable switched MBCs.
kReduced smIgA11 or smIgA21 PC counts were observed in all patients with IgAdef except 2 patients who had decreased smIgA1 MBC counts.
{One CVID case showed detectable but reduced switched PC counts.
#When smIgG2
1 MBCs were present, these subsets were systematically decreased.
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CVID-6 clusters (data not shown).
When considering the 6 CVID clusters, no overall differences
were observed among them regarding age (at time of study and at
diagnosis) and immunoglobulin serum levels, whereas significant
differences were found in the frequency of autoimmunity
(P 5 .02), autoimmune cytopenias (P 5 .02), and (a statistical
trend) hepatomegaly (P5 .06). Subsequent pairwise comparisons
confirmed a similar age and sex distribution and frequency of
recurrent infections (range, 83% to 100%) was observed among
the 6 CVID clusters, except for CVID-6 cases, who were signifi-
cantly older than CVID-2 cases (P 5 .04). In addition, no differ-
ences were observed regarding serum immunoglobulin levels at
diagnosis and the clinical manifestations of the disease among pa-
tients with preserved smIgG1
1 MBCs (CVID-1, CVID-2, and
CVID-3 cases). Conversely, all CVID-4 cases presented with
autoimmunity versus 25% in CVID-1 (P 5 .009), 33% in
CVID-2 (P5 .03), and 50% in CVID-3 (P5 .04) cases, including
a greater frequency of autoimmune cytopenias (67% vs 0% in
CVID-1 and CVID-2 cases and 20% in CVID-3 cases, P <_ .05)
and a tendency (P > .05) toward a greater frequency of systemicautoimmunity (50% vs 25% in CVID-1, 0% in CVID-2, and
10% in CVID-3 cases). Although systemic autoimmunity was
not detected among CVID-5 cases (P 5 .04 vs CVID-4 cases),
these cases more frequently had other adverse clinical features,
such as hepatomegaly (44% vs 5% in CVID-3 cases, P 5 .02),
autoimmunity (89% vs 25% in CVID-1 cases [P 5 .01], 33% in
CVID-2 cases [P < .05], and 50% in CVID-3 cases [P 5 .05]),
and cytopenias (44% vs 0% in CVID-1 cases, P 5 .05).
Finally, CVID-6 cases displayed a mixed clinical profile
between CVID-4 and CVID-5 cases, with a high frequency of
autoimmune cytopenias (50%), as well as hepatomegaly (56%),
bronchiectasis (80%), and enteropathy (78%; Fig 5, B). Addition-
ally, CVID-6 cases presented with granulomatous disease more
frequently than all other CVID patient groups (30% vs 0% to
15%, P5 .06; Fig 5, B, and see Table E12 in this article’s Online
Repository at www.jacionline.org).DISCUSSION
Current IUIS and ESID guidelines for diagnosis and classifi-
cation of PADs rely on antibody serum levels, response to
MBCs PCs
smIgA1
1 MBCs smIgG3
1 MBCs smIgG1
1 MBCs smIgG2
1 MBCs Switched PCs smIgA1 PCs
Normal or Y<2-fold Normal or Y<3-fold Normal* Detectable in
>80% of cases
Y or undetectable in
>90% of cases
Normal or Y<2-fold Normal or Y<1.3-fold Normal* Detectable in
>80% of cases
Undetectable
Normal or Y<12-fold Normal or Y<65-fold Y>1.4-fold or
undetectable
Undetectable
Y>1.2-fold or
undetectable
Y>13-fold or
undetectable
Undetectable Undetectable
Y>15-fold or
undetectable
Undetectable Undetectable Undetectable
Y or undetectablek
Undetectable
Normal or Y<2-fold Normal or Y<3-fold Normal or Y<11-fold Undetectable{
Y>34-fold or
undetectable
Normal or Y<4-fold Normal or Y<12-fold Undetectable
Y>9-fold or
undetectable
Y2-65-fold Y>4-fold or
undetectable
Undetectable
Undetectable Undetectable Undetectable Undetectable
Y>20-fold or
undetectable
Y>9-fold or undetectable Y>80-fold or
undetectable
Undetectable
Undetectable Undetectable Undetectable Undetectable
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BLANCO ET AL 817vaccination, and clinical manifestations of PADs4,5,7 in the
absence of well-defined genetic markers32,33; in addition, an
increased susceptibility to infections and autoimmunity or the ex-
istence of affected familymembers is required for the diagnosis of
IgAdef per the ESID5 (but not IUIS) criteria. Although the num-
ber of affected serum antibody isotypes provides a rough estima-
tion of susceptibility to less (eg, IgAdef) versus more severe
(CVID) disease complications in the short term in patients with
PADs,4,5 it cannot accurately predict the longer-term outcome
of individual patients within each PAD subgroup, particularly af-
ter immunoglobulin replacement therapy. In these settings B-cell
maturation–associated defects identified by using flow cytometry
have proved useful for the diagnosis and classification of patients
with CVID5,18,20 because they more precisely reflect the
medium-term B cell–associated protective potential than their
corresponding serum antibody isotype levels. However, some of
the relationships observed in these studies between B-cell subset
defects in blood and clinical manifestations of the disease14,15,18
have not been confirmed in other studies.16Moreover, patients are
usually classified based on relative B-cell subset numbers,14,15,18
whichmight bemodified by changes in the other subsets,20 and noreference values per age group are used,14,15,18 which might limit
the applicability of these classifications in, for example, chil-
dren.34 In addition, such B-cell defects have been poorly explored
in patients with IgG/Adef and those with IgAdef,19,35 whereas the
blood distribution of B cells and PCs expressing distinct immuno-
globulin subclasses has not been investigated thus far in either pa-
tients with CVID or those with IgAdef.
Here, for the first time, we investigated the distribution ofMBC
and PC subsets that express distinct immunoglobulin isotypes and
IgH subclasses in the blood of patients with PADs and correlated
the altered immune profiles identified with the diagnostic sub-
groups and clinical manifestations of the disease. Because the
blood B-cell compartment is highly dynamic across a patient’s
lifetime,24,36-39 B-cell defects were defined per age group.
Overall, every patient with CVID, IgG/Adef, or IgAdef studied
here showed decreased counts for 1 or more B-cell subsets. This
contrasts with previous flow cytometric studies that detected B-
cell defects in only 6% to 86% of patients with PADs, namely
77% to 86% in patients with CVID,14,15,18,20,23,40,41 6% to 25% in
patients with IgAdef,19,35 and 30% in patients with selective IgG
subclass deficiency (with or without IgAdef).41 This high
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FIG 3. Clustering analysis–based heat map representing all patients with PADs (A) and those with IgAdef (B)
and CVID (C) grouped according to their (altered) bloodMBC and PC subset immune profiles. Each heatmap
represents absolute counts of the different B-cell subsets normalized by the LLN in HDs for the correspond-
ing age group (columns) versus individual cases (rows). Higher red color intensities represent a deeper de-
gree of deficiency in a log10 scale compared with the corresponding age-matched LLN. Individual patients
(rows) are identified by (1) their IUIS (clinical) diagnosis (Fig 3, A; light green for patients with IgAdef, inter-
mediate green for patients with IgG/Adef, and dark green for patients with CVID); (2) their corresponding
ESID IgAdef diagnosis (Fig 3, B), including IgAdef cases that fulfilled (black) or not (gray) the ESID criteria
for IgAdef; and (3) CVID EUROclass classification subgroup (Fig 3, C), smB1CD21normal, smB1CD21lo,
smB2CD21normal, smB2CD21lo, and B2 cells from lighter to darker violet. The here-defined PAD-1 to PAD-
5 (Fig 3, A), IgAdef-1 and IgAdef-2 (Fig 3, B), and CVID-1 to CVID-6 (Fig 3, C) clusters identified by using
the K-means algorithm, as well as the main characteristics of these groups, are depicted at the right side
of each heat map. Black arrows indicate those MBC and PC subsets that contributed most to the specific
identification of each patient cluster.
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FIG 4. Illustrating dot plot examples of the numeric distribution of blood unswitched and switchedMBC and
PC subsets expressing different immunoglobulin isotypes and subclasses in a representative HD (A) and in
representative patients with IgAdef (B) and CVID (C). Each plot corresponds to 3-dimensional Automated
Population Separator (APS) views of principal component 1 (PC1) versus PC2 versus PC3 of the distinct sub-
sets of MBCs and PCs defined by the immunoglobulin isotype and subclass expressed: IgM(D1) in green,
IgG1 in light blue, IgG2 in intermediate blue, IgG3 in dark blue, IgG4 in black, IgA1 in orange, IgA2 in yellow,
and IgD in violet. Additional cases from each group of patients with PADs are displayed in Figs E5 and E6.
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FIG 5. Frequency of distinct clinical manifestations of PADs and the existence (vs absence) of affected
familymembers among the distinct clusters (ie, groups) of patients with IgAdef and those with CVID defined
by their distinct patterns of altered blood B-cell and PC subset counts. Radar charts represent the percentage
of patients with IgAdef (A) and patients with CVID (B) presenting with each type of clinical manifestation of
the disease and the presence of family members affected by PADs. Colored lines indicate the distinct patient
groups as defined by clustering analysis based on the B-cell and PC subset defects identified (see also Fig 3).
#P <_ .05 for patients with IgAdef-1 versus IgAdef-2. aP <_ .05 for CVID-1 versus CVID-4. bP <_ .05 for CVID-1
versus CVID-5. cP <_ .05 for CVID-1 versus CVID-6. dP <_ .05 for CVID-2 versus CVID-4. eP <_ .05 for CVID-2 versus
CVID-6. fP <_ .05 for CVID-3 versus CVID-4. gP <_ .05 for CVID-3 versus CVID-5. hP <_ .05 for CVID-3 versus CVID-6.
iP <_ .05 for CVID-4 versus CVID-5. jP <_ .05 for CVID-5 versus CVID-6. AI, Autoimmunity.
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2019
820 BLANCO ET ALfrequency of B-cell defects most likely reflects the more detailed
dissection of the blood B-cell and PC compartments together with
the greater sensitivity of our method versus previous methods, use
of age-matched reference ranges, or both. However, despite thehigh sensitivity of the flow cytometric approach used here (similar
to that of minimal residual disease detection by using next-
generation flow25,42), several minor B-cell subsets, particularly
within the smIgG1 PC compartment (ie, smIgG1
1 to smIgG4
1
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2 or more age groups, limiting their potential diagnostic utility.
Consequently, these subsets were not considered in the present
study. Acquisition of greater numbers of cells with a greater sensi-
tivity will become feasible soon with the new generation of high-
speed cytometers and might overcome this limitation.
Recently produced short-lived blood PCs,43 particularly IgA1
PCs, emerged as the most sensitive population for diagnosis of
PADs, followed by switched and nonswitched MBCs, with pro-
gressively more severe immunologic defects in the spectrum of
IgAdef to IgG/Adef and CVID. Thus decreased smIgA1
1 and/
or smIgA2
1 PC counts were found in all patients with PADs,
except in 2 patients with IgAdef, who showed reduced smIgA1
1
and smIgA2
1 MBC counts. In addition, decreased total and/or
switched PC counts emerged as a hallmark of CVID, which is
in line with previous bone marrow and lymph node findings.44,45
Of note, patients with IgAdef showed cellular defects typically
restricted to smIgA1 PCs and MBCs, despite IgG1 MBC and
PC counts also being decreased in 15% and 29% of patients
with IgAdef versus 30% and 90% patients with IgG/Adef and
90% and 98% patients with CVID. Nevertheless, compared
with a previous study22 in which less than 10% of patients with
IgAdef had smIgA1 MBCs, a greater percentage of our patients
with IgAdef showed circulating smIgA1 MBCs (50%), PCs
(approximately 40%), or both. This discrepancy is probably
caused by the greater sensitivity of our EuroFlow strategy and
method with 5 3 106 or more (vs 5 3 104) cells analyzed.22
Our findings are in line with those of previous studies
demonstrating Sa-switch recombination in blood B cells from 2
of 4 patients with IgAdef.46 Interestingly, patients with IgAdef
who showed a preserved IgA-switching capacity (IgAdef-1 cases)
displayed a milder clinical phenotype, with less risk factors for
CVID progression (eg, autoimmunity)47 but a similar prevalence
of recurrent respiratory tract infections. In addition, they were
younger (both at presentation and at time of analysis) than
IgAdef-2 cases, which could potentially reflect progressive accu-
mulation of more severe defects in blood IgA1MBCs and PCs in
parallel to a greater frequency and severity of clinical manifesta-
tions. However, all cases categorized as IgAdef-1 that have been
re-evaluated (11/32) after a median follow-up of 25 months
(range, 10-52 months) continue to show preserved IgA-
switching capacity (data not shown), and none of the 26
IgAdef-2 cases followed since their inclusion in this study have
evolved to CVID (median follow-up, 2 years; data not shown).
Nonetheless, longer follow-up times are needed to rule out an ef-
fect of age at diagnosis on the altered blood B-cell immune profile
and clinical manifestations of patients with IgAdef. Altogether,
these findings suggest that detailed evaluation of blood B-cell
and PC defects might contribute to an improved classification
and clinical management of IgAdef patients.
Complete lack of blood switched PCs was the hallmark of
CVID. Although reduced switched MBC counts have been
extensively reported in patients with CVID,14-16,18,20 this is the
first time that these cells were dissected at the immunoglobulin
subclass level, similar to what is routinely done for serum IgG1-
4 levels. Progressive deterioration in IgG-switching capacity
was observed in MBCs of patients with CVID, which directly
correlated with their consecutive location in the IGHC gene locus:
IgM < IgG3 < IgG1 < IgG2. In line with these results, Piqueras
et al14 showed a similar pattern of reduced mRNA expression
for the different immunoglobulin isotypes/immunoglobulinsubclasses: IgM > IgG3 >_ IgG1 > IgG2 > IgA1 > IgA2 > IgG4.
At present, it is well established that downstream IgG subclasses
are produced, at least in part, by consecutive switching of B-cells
during repeated rounds ofMBC response,48-51 leading to a greater
frequency of somatic hypermutation48,50,51 and switch regions
bearing remnants of indirect class-switching50 in cells expressing
downstream immunoglobulin isotypes/immunoglobulin sub-
classes. Interestingly, we recently identified a similar pattern of
sequential production of MBC expressing distinct immunoglob-
ulin subclasses during a lifetime.24
These findings, together with recent observations using
genome-wide sequencing approaches, suggest that consecutive
switching along the IGHC locus might deteriorate in patients with
PADs, possibly because of combined hypomorphic/deleterious
variants,52-54 haploinsufficient genes,55-58 and epigenetic modifi-
cations59 involving B-cell response pathways rather than a single
genetic defect. Progressive deterioration of sequential class-
switching along the IGHC locus, along with reduced MBCs and
lack of PCs, leads to a progressively more restricted repertoire
and decreased functional capacity of MBCs expressing down-
stream IgG subclasses. Of note, previous flow cytometric ap-
proaches typically excluded patients with CVID with less than
1% B cells from further analyses (and subclassification) caused
by insufficient B-cell numbers for robust dissection of its major
subsets.15,18 However, here we were able to identify B cells also
in all patients with CVIDs presenting less than 1% B cells,
including circulating blood naive B cells in 8 of 9 cases and
MBCs in 4 of 9 cases; this is in contrast to BTK-deficient patients
evaluated with this same highly sensitive approach, who system-
atically showed undetectable peripheral blood B cells (data not
shown).
Among different approaches used to categorize CVID, the
EUROclass classification (see Table E11) is the most widely used
because of its clinical utility. This classification allows us to relate
alterations in the distribution of peripheral blood B-cell subsets
with the presence of clinical manifestations, such as a decrease
in MBC counts (smB2 group) and the occurrence of splenomeg-
aly, as also confirmed here (see Table E13 in this article’s Online
Repository at www.jacionline.org). In this regard our proposed
stratification criteria for CVID into CVID-1 to CVID-6 clusters
based on MBC immunoglobulin isotype and IgH-subclass subset
immune profile in blood also showed association with other dis-
ease features (eg, autoimmune cytopenias and hepatomegaly)
that have been related to a lower survival in patients with
CVID10 but that did not correlate with the EUROclass classifica-
tion either in the present or other larger previously reported CVID
patient series.18 In addition, the highly sensitive approach used
here allowed detection of low bloodMBC and PC counts express-
ing IgG1 to IgG4 and IgA1 to IgA2 subclasses, demonstrating that
most patients with CVID retain the ability for class-switching,
including the great majority (>70%) of smB2 cases presenting
with dramatically reduced numbers of switched MBCs.18 This
is consistent with more laborious functional studies that demon-
strated the (residual) capacity of B cells to produce IgG, also
among smB2 patients.21 In fact, our EuroFlow strategy for highly
sensitive immunoglobulin subclass analysis of blood B cells and
PCs identified 6 CVID subgroups with different IgG-switching
patterns and clinical profiles, even within smB2 patients with
CVIDs. The 3 clinically milder subgroups included patients
capable of producing MBCs of the (first 3) IgM/IgD, IgG3, and
IgG1 immunoglobulin isotypes/subclasses located upstream in
J ALLERGY CLIN IMMUNOL
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1 and IgA1 MBC
counts), who might require less IgG substitution therapy.21 In
fact, despite patients of all groups having a greater frequency of
infection, those within the CVID-1 to CVID-3 groups required
less hospital care (data not shown). CVID-4 cases were still
capable of CD271 unswitched MBC production and typically
presented with cytopenias, such as in patients with hyper-IgM
syndromes.60-62 However, they had no PCs (including no IgM1
PCs in all but 1 case), and they showed a typical CVID-related
serum antibody profile in the absence of in vitro functional defects
associated with hyper-IgM syndromes (data not shown).63 Inter-
estingly, 3 of 4 patients with rheumatoid arthritis (an immune
complex–mediated autoimmune disease64) in our series clustered
together in the CVID-4 cluster (data not shown), which only has
preserved IgM11IgD1 MBCs.
The 2 clinically more severe CVID-5 and (particularly) CVID-
6 patient subgroups had dramatically decreased CD271 un-
switched and switched MBC counts, except for
CD272CD212IgG3
1 MBC counts, which were found to be
almost normal in CVID-5 (but not CVID-6) cases. From the clin-
ical point of view, CVID-5 and CVID-6 cases specifically showed
disease symptoms (eg, organomegalies) reflecting an impaired
ability to mount germinal center (GC) responses.24,50,65 Alto-
gether, these findings suggest that even if the residual
CD272CD212smIgG3
1MBCs could offer some immune protec-
tion in CVID-5 cases, in CVID-5 and CVID-6 cases the underly-
ing immune dysregulation leads to a polyclonal lymphocytic
infiltration of secondary lymphoid tissues previously associated
with increased risk for lymphoid malignancy in patients with
CVID.66 In fact, all patients with hematologic tumors were clus-
tered as CVID-5 and CVID-6 cases (see Table E12). Although it is
tempting to hypothesize that such stepwise deterioration of IgG-
switching capacity might reflect disease progression, no signifi-
cant differences in age (or time from diagnosis) were observed
among the above CVID patient subgroups (except for CVID-6
cases who were older at the time of analysis than CVID-2 cases
and the time from diagnosis, which was greater in CVID-6 vs
CVID-2 and CVID-3 cases, data not shown).
The most severe CVID immunologic phenotype, CVID-6, also
showed significantly reduced pre-GC B-cell counts, reflecting a
markedly defective bone marrow B-cell production.18,20,45 Most
blood B cells in these patients showed an immature/transitional
phenotype, reflecting their premature egress from bone marrow,43
whereas residual naive B cells were enriched in the minor CD21lo
naive B-cell subset. Reduced pre-GC B-cell counts, together with
the low in vitro response of both immature and CD21lo naive B
cells,43,67 might explain the marked antigen-experienced B-cell
defect involving all immunoglobulin isotypes found in CVID-6
cases. In line with previous observations,20 these patients also
had decreased naive T CD41 and T CD81 counts versus age-
matched HDs and other patients with CVID (data not shown),
but they did not fulfill the diagnostic criteria for late-onset com-
bined immunodeficiency.5 The potential existence of underlying
hypomorphic defects and variants of genes related to the produc-
tion of lymphocytes (RAG, DCLRE1C, and NHEJ1) previously
related to CVID-like clinical phenotypes remains to be more
deeply investigated in these CVID-6 cases.52-54
In summary, detailed dissection of circulating MBCs and PCs
in patients with PADs into subsets expressing distinct immuno-
globulin subclasses provides complementary information to
serum antibody isotype levels and might contribute to a betterunderstanding of the pathogenesis of PADs and an improved
diagnosis, subclassification, and monitoring (particularly in case
of immunoglobulin replacement therapy) of the disease. Blood
PCs emerged here as the most sensitive diagnostic blood cellular
compartment, whereas analysis of blood MBC subsets appeared
informative to discriminate patients with different clinical pro-
files. However, further multicentric studies in large age-matched
case-control cohorts are needed to replicate and validate the
clinical utility and feasibility of our proposed approach for
detailed and sensitive dissection of blood B-cell and PC subsets
for the diagnosis and classification of PADs. At the same time, use
of EuroFlow databases and tools for automated gating and
reporting of flow cytometric data will facilitate its implementa-
tion in routine diagnostics.68,69
Key messages
d Evaluation of blood B cells and PCs expressing distinct
immunoglobulin subclasses provides a new highly sensi-
tive approach for identification of specific B-cell defects
of potential diagnostic relevance in patients with PADs.
d Detailed dissection of blood MBC and PC subsets express-
ing different immunoglobulin subclasses identifies distinct
deficient immune profiles in patients with primary anti-
body deficiencies, which correlate with both the diag-
nostic subtype and clinical manifestations of the disease.
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